July 31, 2006 -- Repligen won an important court battle in its patent fight against ImClone; Pozen will respond to the approvable letter it received for Trexima, its migraine drug, without new clinical tests; Novavax has designed a vaccine for a new strain of bird flu; Schering said that sargramostim failed a trial as a therapy for Crohn’s disease; Xoma received a $16 million contract from the government to fight botulism; Merck submitted a new diabetes drug to the FDA for approval; CytRx completed the Phase I trial of a new HIV DNA + protein vaccine; Abbott received FDA approval for Humira as a treatment for ankylosing spondyltitis; and Pfizer surprised the street by naming its general counsel, Jeffrey Kindler, as CEO, replacing Hank McKinnell early. The Centient Biotech 200™ ended the session 16 points higher at 3671.79, a gain of .45%. More details...
